Very well put. Speed bumps are to be expected in pre-revenue biotech. That is all the FDA letter was a speed bump with an admonishion to slow down and generate more data. That is what will happen in the 4 dose Brazil trial run by a top notch world class CRO. If those trial pan out CYDY might 5x or 10x from here as early as August or September.